Compare FURY & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FURY | BNR |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.8M | 126.5M |
| IPO Year | 2011 | 2019 |
| Metric | FURY | BNR |
|---|---|---|
| Price | $0.57 | $11.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.70 | N/A |
| AVG Volume (30 Days) | ★ 320.9K | 36.6K |
| Earning Date | 08-11-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $6.79 |
| 52 Week High | $1.02 | $41.72 |
| Indicator | FURY | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | N/A |
| Support Level | $0.51 | N/A |
| Resistance Level | $0.57 | N/A |
| Average True Range (ATR) | 0.03 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 1.98 | 0.00 |
Fury Gold Mines Ltd is a Canadian-focused high-grade gold exploration company. The company's projects are strategically positioned in two prolific mining regions: the Eeyou Istchee James Bay Region of Quebec and the Kitikmeot Region in Nunavut. Fury Gold's project portfolio comprises the Committee Bay gold project in Nunavut, and the Eau Claire gold, Sakami gold, Elmer East gold and lithium, and Eleonore South gold projects in Quebec. Additionally, it also owns interests in the Kipawa rare earths project and has full ownership of the Zeus heavy rare earths project, both located in the Temiscamingue region of Quebec. The company operates in two reportable segments: Quebec and Nunavut.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.